Document is current
Any future updates will be listed below
-
Authors
Kian, Andrea C.
Gupta, Mahima
Hong, Heeju
Rivera, Kálery La Luz
Pandey, Nil
Mossburg, Katherine J.
Rosario-Berrios, Derick N.
Maidment, Portia S. N.
Hanna, Andrew R.
Singh, Priyash
Xiang, Zhenting
Kikkawa, Jay
Issadore, David
Maidment, Andrew D. A.
Koo, Hyun
Cormode, David P.
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01-DE025848)
National Institutes of Health (R01-EB036942)
- License Information
-
More Information
Article History
Received: 15 November 2025
Accepted: 20 February 2026
First Online: 26 February 2026
Declarations
:
: DPC and ADAM are named as inventors on patent applications concerning silver-based contrast agents. They also hold stock in Daimroc Imaging, a company that is seeking to commercialize such agents. DPC and HK are named as inventors on patent applications concerning iron oxide-based nanoparticles. DI is named as an inventor on patent applications concerning methods of microfluidic nanoparticle production.
